In December of 2017, EnginMed announced the successful completion of over RMB10 million Series A financing. The company extended and completed the Series A round with investment from Ningbo Ruihui Tianchen Equity Investment. YinCapital acted as the exclusive financial advisor to EnginMed in its latest financing round that was just completed.

EnginMed specialize in developing and manufacturing the Noninvasive Tissue Oximeter Using Near Infrared Spectroscopy (NIRS). Monitoring blood oxygen saturation and hemoglobin concentration in human tissue noninvasively and continuously using NIRS is a new technique. It has been applied clinically in assessing the cerebral impairments and developments of neonates, monitoring cerebral oxygenation during CPB to protect cerebral tissue against hypoxia, monitoring blood transportation in the transplanted tissues, and assessing the metabolic functions of skeletal muscles.

This project was led by Professor Ding haishu of Tsinghua University and EnginMed was authorized exclusively of its IP. Till now, EnginMed occupies more than 60% market share and over 60 A-Grade Hospitals in China has equipped with its oximeter.

EnginMed is using the proceeds from this round to accelerate the extension of its platform infrastructure and expand market share both domestically and overseas.

Go back »